A Swiss court has ruled that while Serono S.A. may not advertise its multiple sclerosis data to the public or to healthcare professionals, it can distribute information on the EVIDENCE study exclusively to healthcare professionals. However, just what the difference is between "distribute information" and "advertise" is not clear.

As a result, the ruling allowed both Serono and Biogen Inc. to declare victory in their dispute over what Serono can do with data from its trial comparing its Rebif beta interferon and BGEN's Avonex beta interferon.